- Zacks•last month
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
|Day's Range||0.00 - 0.00|
|Avg Vol (3m)||436,654|
As of 10:59 AM EDT. Market closed.